JP2023521763A - 抗ｐｈｆ－タウ抗体及びその使用 - Google Patents

抗ｐｈｆ－タウ抗体及びその使用 Download PDF

Info

Publication number
JP2023521763A
JP2023521763A JP2022561415A JP2022561415A JP2023521763A JP 2023521763 A JP2023521763 A JP 2023521763A JP 2022561415 A JP2022561415 A JP 2022561415A JP 2022561415 A JP2022561415 A JP 2022561415A JP 2023521763 A JP2023521763 A JP 2023521763A
Authority
JP
Japan
Prior art keywords
seq
polypeptide sequence
variable region
heavy chain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521763A5 (https=
Inventor
コーレン，クリストフ ヴァン
マーケン，マーク
ナンジュンダ，ラペシュ
シング，サンジャヤ
ポルテ，シェリー ラ
ルオ，ジンクアン
ジャイプラサート，ファービー
ヴェンカタラマニ，サティヤデヴィ
ガネサン，ラージクマール
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023521763A publication Critical patent/JP2023521763A/ja
Publication of JP2023521763A5 publication Critical patent/JP2023521763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2022561415A 2020-04-08 2021-04-07 抗ｐｈｆ－タウ抗体及びその使用 Pending JP2023521763A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US63/007,118 2020-04-08
US202063026387P 2020-05-18 2020-05-18
US63/026,387 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023521763A true JP2023521763A (ja) 2023-05-25
JP2023521763A5 JP2023521763A5 (https=) 2024-04-09

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561415A Pending JP2023521763A (ja) 2020-04-08 2021-04-07 抗ｐｈｆ－タウ抗体及びその使用

Country Status (20)

Country Link
US (1) US20230151083A1 (https=)
EP (1) EP4132569A4 (https=)
JP (1) JP2023521763A (https=)
KR (1) KR20220166308A (https=)
CN (1) CN115697393A (https=)
AU (1) AU2021251486A1 (https=)
BR (1) BR112022020410A2 (https=)
CA (1) CA3179914A1 (https=)
CL (1) CL2022002766A1 (https=)
CO (1) CO2022015737A2 (https=)
CR (1) CR20220505A (https=)
DO (1) DOP2022000218A (https=)
EC (1) ECSP22078815A (https=)
IL (1) IL297231A (https=)
JO (1) JOP20220255A1 (https=)
MX (1) MX2022012628A (https=)
PE (1) PE20230385A1 (https=)
PH (1) PH12022553035A1 (https=)
TW (1) TW202204402A (https=)
WO (1) WO2021205359A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
CA3254442A1 (en) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US20180194832A1 (en) * 2015-07-06 2018-07-12 Ucb Biopharma Sprl Tau-binding antibodies
US20180265575A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
US10591492B2 (en) * 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
CA3179922A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Anti-cd98 antibodies and uses thereof
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US20180194832A1 (en) * 2015-07-06 2018-07-12 Ucb Biopharma Sprl Tau-binding antibodies
US20180265575A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Also Published As

Publication number Publication date
CL2022002766A1 (es) 2023-04-21
CO2022015737A2 (es) 2023-02-27
CA3179914A1 (en) 2021-10-14
WO2021205359A1 (en) 2021-10-14
AU2021251486A1 (en) 2022-12-08
CN115697393A (zh) 2023-02-03
BR112022020410A2 (pt) 2023-01-03
EP4132569A1 (en) 2023-02-15
PE20230385A1 (es) 2023-03-06
IL297231A (en) 2022-12-01
EP4132569A4 (en) 2024-07-31
US20230151083A1 (en) 2023-05-18
MX2022012628A (es) 2023-01-11
ECSP22078815A (es) 2022-11-30
PH12022553035A1 (en) 2024-05-13
JOP20220255A1 (ar) 2022-10-06
KR20220166308A (ko) 2022-12-16
DOP2022000218A (es) 2023-04-30
TW202204402A (zh) 2022-02-01
CR20220505A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
US20230047413A1 (en) Anti-PHF-Tau Antibodies and Uses Thereof
JP2023521763A (ja) 抗ｐｈｆ－タウ抗体及びその使用
EP2794654A2 (en) Anti-phf-tau antibodies and their uses
WO2019171259A1 (en) Anti-phf-tau antibodies and uses thereof
US20240150451A1 (en) Anti-tau antibodies and uses thereof
EA047298B1 (ru) Антитела к phf-тау и их применение
EA049614B1 (ru) Анти-псф-тау-антитела и способы их применения
BR112019019049B1 (pt) Anticorpos antiphf-tau, ácido nucleico isolado, vetor, e composição farmacêutica
BR122023021958B1 (pt) Anticorpos anti-phf-tau, composição farmacêutica, e método in vitro de produção dos referidos anticorpos
BR122023021947B1 (pt) Usos de anticorpos anti-phf-tau

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303